Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04307355 · ClinicalTrials.gov registry record · NA
Continuous Diffusion of Oxygen Treatment for Incision Wounds
A NA study of Surgical Wound and Breast Surgery, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT04307355: Completed NA study of Surgical Wound and Breast Surgery, sponsored by Baylor College of Medicine.
NCT04307355 is a NA study of Surgical Wound and Breast Surgery that has completed, run by Baylor College of Medicine. The registered enrollment target is 23 participants, below the 94-participant average among 17 other Surgical Wound trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04307355, a NA study of Surgical Wound and Breast Surgery, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an exploratory randomized controlled trial study to test feasibility, acceptability, and proof of concept efficacy of Continuous Diffusion of Oxygen (CDO) adjunct therapy for decreasing healing time and reducing tissue necrosis post breast reconstruction. The investigator will assess the benefit of this novel adjunct therapy on successful closure, tissue oxygenation, scar appearance, and patients centered outcomes including perception of benefit, pain, sleep quality, and quality of life. Eligible subjects will be randomly (ratio 1:1) assigned to either intervention group (IG) or control group (CG) and will be followed for four weeks. Both groups will receive standard of care for wound treatment. IG will also receive CDO adjunct therapy using a novel dressing, which facilitates continuously supplies oxygen to the wound inside the wound dressing using a portable device named TransCu O2. The study device TransCu O2® is a Class II medical device which has US Food and Drug Administration (FDA) 510(k) clearance, CE-Mark approval and a Health Canada license for the treatment of wounds. Outcomes will be assessed on weekly-basis up to 4 weeks.
Primary Outcome
Wound size will be traced and quantified using a wound imaging system (Snapshot, Kent Imaging)
Conditions Studied
Interventions
- DEVICE Transcu O2®
- OTHER Tegaderm
- OTHER Silagen
Study Locations (1)
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2023-08-28 |
| Phase | NA |
What the finished NCT04307355 record still lists
NCT04307355 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 94-participant average among 17 other Surgical Wound trials with a reported enrollment target (76% lower).
The record links to 4 conditions, with Surgical Wound appearing as the primary indexed condition, and to 3 interventions - of which Transcu O2® is the first listed.
NCT04307355 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04307355 about?
NCT04307355 is a clinical study titled "Continuous Diffusion of Oxygen Treatment for Incision Wounds". This is an exploratory randomized controlled trial study to test feasibility, acceptability, and proof of concept efficacy of Continuous Diffusion of Oxygen (CDO) adjunct therapy for decreasing healing time and reducing tissue necrosis post breast reconstruction. The investigator will assess the ben...
What is the current status of trial NCT04307355?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2021-06-01. Estimated completion is 2023-08-28.
What conditions does trial NCT04307355 study?
This clinical trial studies the following conditions: Surgical Wound, Breast Surgery, Mammoplasty, Incision Wound.
What interventions are being tested in trial NCT04307355?
The interventions under investigation include: Transcu O2® (DEVICE), Tegaderm (OTHER), Silagen (OTHER).
Who is sponsoring clinical trial NCT04307355?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04307355 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Surgical Wound
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04307355's enrollment target sits among peer trials
23 17th of 17 higher than 1 of 17 other Surgical Wound trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Surgical Wound trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Versus Delayed Bathing of Orthopaedic Surgical Wounds
RECRUITING · NA
-
Multicenter Single-arm Trial to Investigate Clinical Outcomes When Cohealyx™ is Used for Full Thickness Wounds
ACTIVE NOT RECRUITING · NA
-
Influence of Sun Protection and Linear Repair of Cutaneous Surgical Defects
ACTIVE NOT RECRUITING · NA
-
Suture Closure Trial
ACTIVE NOT RECRUITING · NA
-
Randomized Controlled Trial to Investigate Clinical Outcomes and Associated Costs When PermeaDerm is Used as Temporary Dressing for Surgical Wounds
ACTIVE NOT RECRUITING · NA
-
RESPECT Trial - (Rapid Extravascular Sealing Via PercutanEous Collagen ImplanT)
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI